3:39 PM
Mar 09, 2018
 |  BC Extra  |  Clinical News

Phase I/II of Roche PNH candidate temporarily halted

Editor's Note: This article was updated on Mar 09, 2018 at 5:03 PM PST

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said enrollment was temporarily stopped in the Phase I/II COMPOSER trial evaluating RG6107 (SKY59) in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) after two patients who received RG6107 developed mild to moderate symptoms of...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >